Be Biopharma

Be Biopharma is a leader in developing engineered B cells as a novel cellular drug. B cells are one of the most unique and versatile cell populations in the body, playing a key role in humoral immunity and modulating the behavior of immune cells in tumors and chronically inflamed tissues. They are among the most prolific protein factories in the human body, transporting to tissues in a targeted manner and capable of engrafting in niches for decades.Our goal is to create a new category of cellular therapies by precisely harnessing the rich biology and intrinsic drug-like properties of B cells. B cell therapies address some of the major challenges facing current cell and gene therapies, such as the inability to redose, unpredictable PK/PD, and the need to precondition patients with toxic chemotherapy regimens before administering cell therapy. Designed to be durable, redosable, and deliverable without toxic conditioning, B cell drugs open new avenues for halting or reversing severe diseases like cancer, autoimmune disorders, infectious diseases, and enzyme deficiencies. Founded by Longwood Fund and pioneers in B cell engineering, Dr. David Rawlings and Dr. Richard James, Be Biopharma is reimagining medicine through the power of B cell therapies.